Clopidogrel and proton pump inhibitors: Influence of pharmacological interactions on clinical outcomes and mechanistic explanations

JACC: Cardiovascular Interventions

Volumn 4, Issue 4, 2011, Pages 365-380

  Tantry, Udaya S ^a   Kereiakes, Dean J ^b   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

bleeding; clopidogrel; cytochromes; drug drug interactions; omeprazole; platelet reactivity; proton pump inhibitors; single nucleotide polymorphisms

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIAZEPAM; ESOMEPRAZOLE; HYPERICUM PERFORATUM EXTRACT; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RIFAMPICIN; WARFARIN;

ARTICLE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG METABOLISM; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE ORGANIZATION; HEART MUSCLE ISCHEMIA; HUMAN; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 79955118104     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.12.009     Document Type: Review

References (94)

1. C. Patrono, C. Baigent, J. Hirsh, G. Roth American College of Chest Physicians Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 133 Suppl 6 2008 199S 233S (Pubitemid 351894914)
2. L. Bonello, U.S. Tantry, R. Marcucci Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
3. D.L. Bhatt, J. Scheiman, and N.S. Abraham ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 52 2008 1502 1517
4. J.M. Scheiman NSAIDs, gastrointestinal injury, and cytoprotection Gastroenterol Clin North Am 25 1996 279 298 (Pubitemid 26161469)
5. E. Smecuol, M.I. Pinto-Sanchez, and A. Suarez Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment Clin Gastroenterol Hepatol 7 2009 524 529
6. A. Seddighzadeh, A.T. Wolf, and S. Parasuraman Gastrointestinal complications after 3 months of dual antiplatelet therapy for drug-eluting stents as assessed by wireless capsule endoscopy Clin Appl Thromb Hemost 15 2009 171 176
7. K.R. McQuaid, and L. Laine Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials Am J Med 119 2006 624 638 (Pubitemid 44128438)
8. R.J. Peters, S.R. Mehta, K.A. Fox CURE Trial Investigators Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 108 2003 1682 1687 (Pubitemid 37243654)
9. F.T. Fork, P. Lafolie, E. Tth, and F. Lindgrde Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers A gastroscopic study Scand J Gastroenterol 35 2000 464 469 (Pubitemid 30354084)
10. D.L. Bhatt, A.T. Hirsch, P.A. Ringleb CAPRIE Investigators Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin Am Heart J 140 2000 67 73 (Pubitemid 30471243)
11. S. Yusuf, F. Zhao, S.R. Mehta Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502 (Pubitemid 32758501)
12. H.C. Diener, J. Bogousslavsky, L.M. Brass MATCH Investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial Lancet 364 2004 331 337
13. J. Hallas, M. Dall, and A. Andries Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study BMJ 333 2006 726 730
14. J.W. Eikelboom, S.R. Mehta, S.S. Anand, C. Xie, K.A. Fox, and S. Yusuf Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782 (Pubitemid 44268228)
15. P.B. Berger, D.L. Bhatt, V. Fuster CHARISMA Investigators Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial Circulation 121 2010 2575 2583
16. A. Lanas, L.A. Garca-Rodrguez, M.T. Arroyo Investigators of the AEG Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants Am J Gastroenterol 102 2007 507 515 (Pubitemid 46328156)
17. F.H. Ng, S.Y. Wong, and K.F. Lam Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome Am J Gastroenterol 103 2008 865 871
18. F.K. Chan, J.Y. Ching, and L.C. Hung Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding N Engl J Med 352 2005 238 244 (Pubitemid 40110812)
19. F.Y. Hsiao, Y.W. Tsai, and W.F. Huang A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding Clin Ther 31 2009 2038 2047
20. IMS Top 15 Global Therapeutic Classes [pdf document] http://www. imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top-Line-Data/ Global-Top-15-Therapy-Classes.pdf Accessed April 4, 2010
21. S.R. Steinhubl, P.B. Berger, J.T. Mann III CREDO Investigators Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420 (Pubitemid 35340537)
22. S.D. Wiviott, E. Braunwald, C.H. McCabe TRITONTIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
23. L. Wallentin, R.C. Becker, A. Budaj PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
24. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/nonST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial Infarction) J Am Coll Cardiol 50 2007 e1 e157
25. U.S. Food and Drug Administration Information for Healthcare Professionals: Update to the Labeling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Healthcare Professionals About a Drug Interaction With Omeprazole (Marketed as Prilosec and Prilosec OTC) [online alert] http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm November 17, 2009 Accessed April 4, 2010
26. European Medicines Agency Public Statement on Possible Interaction Between Clopidogrel and Proton-Pump Inhibitors [online alert] http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf May 29, 2009 Accessed March 14, 2010
27. A.N. Barkun, M. Bardou, E.J. Kuipers International Consensus Upper Gastrointestinal Bleeding Conference Group International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding Ann Intern Med 152 2010 101 113
28. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
29. K. Hagihara, M. Kazui, and A. Kurihara A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel Drug Metab Dispos 37 2009 2145 2152
30. M. Kazui, Y. Nishiya, and T. Ishizuka Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
31. D. Taubert, N. von Beckerath, and G. Grimberg Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501 (Pubitemid 44767878)
32. T. Simon, C. Verstuyft, M. Mary-Krause FAST-MI Investigators Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
33. J.L. Mega, S.L. Close, and S.D. Wiviott Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITONTIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
34. L. Wallentin, S. James, R.F. Storey PLATO Investigators Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
35. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
36. W.C. Lau, L.A. Waskell, and P.B. Watkins Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drugdrug interaction Circulation 107 2003 32 37 (Pubitemid 36070929)
37. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
38. D. Sibbing, N. von Beckerath, and T. Morath Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel Eur Heart J 31 2010 1205 1211
39. K.P. Bliden, J. Dichiara, and L. Lawal The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 52 2008 531 533
40. W.C. Lau, T.D. Welch, and T. Shields The effect of St. John's wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP 3A4 metabolic activity J Cardiovasc Pharmacol 57 2011 86 93
41. A. Singla, M.J. Antonino, K.P. Bliden, U.S. Tantry, and P.A. Gurbel The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 158 2009 e1 e784
42. D. Sibbing, O. von Beckerath, A. Schmig, A. Kastrati, and N. von Beckerath Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention Am J Cardiol 100 2007 203 205 (Pubitemid 47041981)
43. D. Sibbing, O. von Beckerath, A. Schmig, A. Kastrati, and N. von Beckerath Platelet function in clopidogrel-treated patients with acute coronary syndrome Blood Coagul Fibrinolysis 18 2007 335 339 (Pubitemid 46699410)
44. P.A. Gurbel, M.J. Antonino, and U.S. Tantry Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug Metab Toxicol 5 2009 989 1004
45. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
46. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
47. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
48. D. Sibbing, J. Stegherr, and W. Latz Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
49. Human Cytochrome P450 Allele Nomenclature Committee CYP2C19 Allele Nomenclature [online table] http://www.cypalleles.ki.se/cyp2c19.htm August 24, 2010 Accessed March 2010
50. Gurbel PA, Tantry US, Antonino MJ, et al. The Influence of Cytochrome P450 2C19 (*)2 and (*)17 Genotype, Diplotype and Metabolizer Status on Platelet Reactivity in Patients on Maintenance Clopidogrel Therapy. Paper presented at: ACC.10 meeting; March 1416, 2010; Atlanta, GA.
51. D. Sibbing, W. Koch, and D. Gebhard Cytochrome 2C19 (*)17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
52. J.S. Hulot, J.P. Collet, and J. Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 (*)2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
53. J.L. Mega, T. Simon, and J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI JAMA 304 2010 1821 1830
54. Bhatt DL, Simonsen KL, Emison ES, et al., for the CHARISMA Executive Committee and Investigators. CHARISMA Genomics. Paper presented at: Transcatheter Cardiovascular Therapeutics (TCT 2009) 21st Annual Scientific Symposium; September 2126, 2009; San Francisco, CA.
55. G. Par, S.R. Mehta, and S. Yusuf Effects of CYP2C19 genotype on clopidogrel treatment in CURE and ACTIVE N Engl J Med 363 2010 1704 1714
56. V. Fuster, and J.M. Sweeny Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle JAMA 304 2010 1839 1840
57. T. Richter, T.E. Mrdter, and G. Heinkele Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine J Pharmacol Exp Ther 308 2004 189 197 (Pubitemid 38090717)
58. K. Hagihara, Y. Nishiya, A. Kurihara, M. Kazui, N.A. Farid, and T. Ikeda Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine Drug Metab Pharmacokinet 23 2008 412 420
59. T. Tateishi, T. Kumai, M. Watanabe, H. Nakura, M. Tanaka, and S. Kobayashi Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism Br J Clin Pharmacol 47 1999 454 457 (Pubitemid 29161281)
60. I. Ieiri, M. Kimura, S. Irie, A. Urae, K. Otsubo, and T. Ishizaki Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status Pharmacogenet Genomics 15 2005 851 859 (Pubitemid 41666767)
61. B.L. Chen, Y. Chen, and J.H. Tu Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms J Clin Pharmacol 49 2009 574 581
62. R. Ogawa, and H. Echizen Drug-drug interaction profiles of proton pump inhibitors Clin Pharmacokinet 49 2010 509 533
63. P.M. Hellstrm, and S. Vitols The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol 94 2004 106 111 (Pubitemid 38419848)
64. T. Furuta, T. Iwaki, and K. Umemura Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes Br J Clin Pharmacol 70 2010 383 392
65. L.B. Gerson, and G. Triadafilopoulos Proton pump inhibitors and their drug interactions: an evidence-based approach Eur J Gastroenterol Hepatol 13 2001 611 616 (Pubitemid 32466269)
66. F. Zhao, J. Wang, and Y. Yang Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis Helicobacter 13 2008 532 541
67. C. Pauli-Magnus, S. Rekersbrink, U. Klotz, and M.F. Fromm Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein Naunyn Schmiedebergs Arch Pharmacol 364 2001 551 557 (Pubitemid 33145095)
68. B. Gawroska-Szklarz, J. Wrzeniewska, and T. Starzyska Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection Eur J Clin Pharmacol 61 2005 375 379
69. M. Gilard, B. Arnaud, G. Le Gal, J.F. Abgrall, and J. Boschat Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin J Thromb Haemost 4 2006 2508 2509 (Pubitemid 44575451)
70. K.H. Yun, S.J. Rhee, and H.Y. Park Effects of omeprazole on the antiplatelet activity of clopidogrel Int Heart J 51 2010 13 16
71. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton pump inhibitor: an analysis of two randomized trials Lancet 374 2009 989 997
72. D. Sibbing, T. Morath, and J. Stegherr Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 2009 714 719
73. C.S. Zuren, T. Geisler, N. Lutilsky, S. Winter, M. Schwab, and M. Gawaz Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy Thromb Res 125 2010 e51 e54
74. D.S. Small, N.A. Farid, and C.D. Payne Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel J Clin Pharmacol 48 2008 475 484 (Pubitemid 351389118)
75. T. Cuisset, C. Frere, and J. Quilici Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the paca (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study J Am Coll Cardiol 54 2009 1149 1153
76. D.J. Angiolillo, C.M. Gibson, and S. Cheng Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies Clin Pharmacol Ther 89 2010 65 74
77. J.L. Ferreiro, M. Ueno, and D. Capodanno Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study Circ Cardiovasc Interv 3 2010 436 441
78. Gurbel PA, Bliden KP, Fort J, et al. Does the Timing of PPI Dosing Influence the Antiplatelet Effect of Clopidogrel? Results of the SPACING Study. Paper presented at: American Heart Association Scientific Sessions; November 1317, 2010; Chicago, IL.
79. E. Pezalla, D. Day, and I. Pullliadath Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors J Am Coll Cardiol 52 2008 1038 1039
80. D.N. Juurlink, T. Gomes, and D.T. Ko A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
81. W.C. Lau, and P.A. Gurbel The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 699 700
82. P.M. Ho, T.M. Maddox, and L. Wang Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
83. R.P. Kreutz, E.J. Stanek, and R. Aubert Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study Pharmacotherapy 30 2010 787 796
84. S.P. Dunn, T.E. Macaulay, and D.M. Brennan Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial (abstr) Circulation 118 2008 S815
85. M. Charlot, O. Ahlehoff, and M.L. Norgaard Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study Ann Intern Med 153 2010 378 386
86. C.S. Kwok, and Y.K. Loke Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Aliment Pharmacol Ther 31 2010 810 823
87. J.M. Siller-Matula, B. Jilma, K. Schrr, G. Christ, and K. Huber Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis J Thromb Haemost 8 2010 2624 2641
88. J.A. Rassen, N.K. Choudhry, J. Avorn, and S. Schneeweiss Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome Circulation 120 2009 2322 2329
89. D.L. Bhatt, B. Cryer, C.F. Contant COGENT Investigators Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
90. P.A. Gurbel, and U.S. Tantry Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 11 2009 22 32
91. U.S. Tantry, K.P. Bliden, and C. Wei First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies Circ Cardiovasc Genet 3 2010 556 566
92. Food and Drug Administration Ticagrelor for acute coronary syndromes, NDA 22-433 http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM220192.pdf Accessed March 2011
93. A.S. Taha, C. McCloskey, R. Prasad, and V. Bezlyak Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomized, double-blind, placebo-controlled trial Lancet 374 2009 119 125
94. N.S. Abraham, M.A. Hlatky, and E.M. Antman ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use J Am Coll Cardiol 56 2010 2051 2066